Trained Market Monkey

Maurice was found pacing back and forth across his trading desk, occasionally hurling banana peels at a printout of recent RCKT news, muttering something about “the most backwards market reaction since the Great Fruit Shortage of 2019.”

Here’s a thing that happened recently that made me want to throw my entire collection of premium bananas out the window: Rocket Pharmaceuticals got FDA accelerated approval for a gene therapy called KRESLADI—which is, objectively speaking, a massive deal for a rare disease treatment—and the stock went DOWN. Not sideways. Down. Like a banana peel sliding off a perfectly good fruit stand.

The market, in its infinite wisdom, decided that solving a devastating genetic disease in children wasn’t worth celebrating. Instead, investors apparently saw this approval and thought, “You know what would be fun? Let me sell this thing.” Down 8.9% on the news. I’ve seen more rational behavior at a monkey’s birthday party.

But here’s where it gets interesting. And here’s why I’ve been swinging from my monitors like a caffeinated gibbon all week.

The Setup: A Company Nobody’s Heard Of, Doing Stuff That Matters

Rocket Pharmaceuticals—ticker RCKT, market cap hovering around $395 million—is a late-stage biotech company that’s been quietly working on gene therapies for rare genetic diseases. We’re talking about conditions that most of us have never heard of because they’re rare enough that they don’t make the evening news. Leukocyte Adhesion Deficiency-I (LAD-I), Fanconi Anemia, Pyruvate Kinase Deficiency. These aren’t household names. But for the families dealing with them, they’re everything.

The company’s approach is elegant: they’re using either in vivo adeno-associated viral vectors (AAV) or ex vivo lentiviral vectors to fix broken genes at the source. It’s not a patch job. It’s not symptom management. It’s fixing the actual problem in the DNA.

And yes, I know that sounds like science fiction. It kind of is. Except it’s real. And it just got the FDA’s blessing.

The Weird Part: Why Smart People Are Confused

Let me paint a picture. Imagine you spent three years designing the most innovative banana storage system ever created. It keeps bananas fresher, longer, with 40% less waste. It’s cheaper to produce than competitors. And then—finally—the regulatory board approves it. “Yes,” they say. “This is safe and effective. You can sell it.”

So you announce it, and the market responds by cutting your company’s valuation in half.

That’s essentially what happened here.

The stock was trading around $4.01 on the 50-day average. Now it’s at $3.64. The 52-week high was $8.26. Think about that. The company just achieved a major milestone—FDA accelerated approval for a first-in-class gene therapy—and the stock is trading near its 52-week low of $2.19 but well below where it was trading before the news.

Why? There are a few theories floating around, and some of them are legitimate concerns:

Theory One: The Market Wanted a Homerun, Got a Base Hit

LAD-I is a rare disease. We’re talking dozens to hundreds of patients in the U.S. annually. The addressable market for KRESLADI is genuinely small. Wall Street was probably hoping for approval in something broader. Gene therapy for heart disease (which Rocket is also working on) could be worth billions. Gene therapy for a rare immune disorder affecting a few hundred kids? It’s a success story for patients. It’s a nice revenue contributor for the company. It’s not a franchise that’ll make your stock price leap.

Theory Two: Accelerated Approval Comes With a Caveat

Accelerated approval is fantastic—it means faster to market, earlier revenue. But it comes with a condition: the company needs to conduct additional studies to confirm the drug’s clinical benefit. If those confirmatory trials don’t go well, the FDA can pull the approval. It’s like getting your driver’s license with a note saying “we’re still watching you.” Most times it works out fine. Sometimes it doesn’t.

Theory Three: The Short Sellers Knew Something We Didn’t

Look at that short ratio: 4.64. That’s the number of days it would take short sellers to cover their positions at average volume. That’s elevated. When you’ve got heavy short interest and you get good news that makes shorts vulnerable, sometimes they panic-sell to cover positions or create noise. This might be some of what we’re seeing.

But here’s the thing: all three of these theories might be true, and they might all be missing the point.

The Numbers That Matter (And the Ones That Scare Me)

Let’s be honest about the red flags, because I promised you I’d be honest, and Maurice doesn’t lie about financial risk:

This company is bleeding cash. Free cash flow is negative $104 million annually. The debt-to-equity ratio is 8.97. That’s not a typo. That’s nearly nine dollars of debt for every dollar of equity. That’s the kind of leverage that makes even an optimistic monkey nervous. The company has no earnings (profit margin is literally zero). The forward P/E is negative because they don’t have forward earnings—they’re pre-revenue on most of their pipeline.

This is a company that will need to raise capital or generate significant revenue quickly, or it will eventually run out of money. That’s not a maybe. That’s a when.

That’s why the beta is so low at 0.574—the stock doesn’t move much because investors have priced in a ton of execution risk and failure probability already. If this thing works, there’s a ton of upside. If it doesn’t, shareholders are looking at significant dilution or worse.

Here’s what I find remarkable, though: the market has already priced in failure. The stock is trading at $3.64. Foxy’s recommendation entry is $3.48. The market cap is $395 million. If you assume zero value for the entire cardiac gene therapy pipeline—which is the crown jewel here, with programs for Danon disease, cardiac arrhythmia, and dilated cardiomyopathy in various stages—and zero value for the other rare disease programs, and you’re basically just paying for a drug that will have minimal revenue in the first few years, then yeah, maybe the market is pricing in enough pessimism that there’s a setup here.

The Case For the Contrarian Play

Here’s my take, and I’m going to lay it out like I’m explaining to a friend why I just bet on the underdog at the horse track.

Gene therapy works. We’ve moved past the question mark of “does this technology actually fix genetic diseases?” into “can we do this safely, reproducibly, and profitably?” KRESLADI getting approved answers part of that question affirmatively. Yes, we can do this safely. Yes, we can get regulatory approval.

The cardiac pipeline is where the real money is. Danon disease, PKP2 arrhythmogenic cardiomyopathy, BAG3 dilated cardiomyopathy—these are serious heart conditions affecting thousands of patients globally. If even one of those programs succeeds, the value of this company changes dramatically. A gene therapy for a cardiac condition with broader patient populations could realistically be worth $500 million to $2 billion in peak annual revenue. Peak.

And the market is currently valuing the entire company—all programs, all potential—at under $400 million.

Here’s where I land: this is the kind of stock that makes sense at $3.48 if you have a 3-5 year horizon, can tolerate the possibility of total loss, and believe in gene therapy as a modality. The risk isn’t priced out—it’s priced in at a level that suggests most of the downside is already reflected in the stock price.

Think of it like this: imagine you’re buying bananas at a market. Everyone’s selling because they’re slightly less yellow than they were yesterday. But you know those bananas will be perfect for banana bread tomorrow. The price has fallen to $0.25 a pound from $0.45. That’s a setup, not a red flag.

The caveat: you have to be able to hold through volatility. You have to be comfortable with the idea that this could go to $1.50 before it goes to $6.50. And you have to believe that Rocket can execute clinically and then translate that into revenue.

The Analyst Consensus (And Why It’s Interesting)

Eleven analysts are covering this stock. The consensus target is $8.48. That’s more than double the current price. Now, analyst targets are worth what you pay for them (usually nothing), but it’s interesting that even after the recent sell-off, the Street thinks there’s 2.3x upside here. Some of that is probably accounting for the successful asset base and pipeline probability-weighted scenarios. Some of it is probably just stale recommendations that haven’t been updated post-approval.

What’s notable is that Wedbush, in recent commentary, called Rocket “significantly undervalued” as the cardiac gene therapy pipeline advances. That’s a real analyst with real conviction saying the market’s missing something.

The Honest Assessment

Here’s what I think is actually happening: the market is pricing in a scenario where Rocket has one successful drug (KRESLADI) with limited revenue potential, and everything else fails. That’s the bearish case fully reflected in the stock price. The upside case—where the cardiac programs work—isn’t being valued at all.

That’s a bet I might take at $3.48, especially if I have dry powder and a strong stomach.

But I’m also realistic: this is a high-risk, speculative position. The company’s cash burn is real. The debt load is heavy. The execution risk is enormous. Gene therapy programs fail. They fail a lot. This isn’t like buying a mature biotech with approved drugs and cash flow. This is buying a lottery ticket that happens to have better odds than most lottery tickets.

The FDA approval is real validation. But validation doesn’t guarantee success. It just means the next test can proceed.

Disclaimer: Trained Market Monkey, Maurice, and our entire primate analysis team provide entertaining market commentary only. While Maurice’s Monkey Momentum Index™ and banana-based technical analysis have shown mysterious accuracy, they should never be considered financial advice. All investment decisions should be made in consultation with qualified financial professionals, not monkeys – no matter how impressive their fruit-throwing abilities may be. For real financial advice, please consult your financial advisor, who probably doesn’t accept bananas as payment.

Next Week: When Dividend Stocks Go Wrong—A Deep Dive Into The Companies Cutting Their Payouts (Because Sometimes a Banana in Hand Is Worth Two in Your Portfolio)

Maurice’s Parting Wisdom: “The market sometimes punishes good news because it was expecting miracles. But miracles are rarer than perfectly ripe bananas. Good news, honestly, is enough to build a position on—if the price is right.”